Wikisage, the free encyclopedia of the second generation, is digital heritage

Belzutifan

From Wikisage

Revision as of 23:18, 13 August 2021 by Penarc (talk | contribs) (Created page with "Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von Hippel-Lindau disease. Belzutifan is an inhibitor of hypoxia-inducible facto...")

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Jump to navigation Jump to search

Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von Hippel-Lindau disease.

Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α).

Belzutifan is the first drug to be awarded an "innovation passport" by the UK Medicines and Healthcare products Regulatory Agency (MHRA)^[1]

ATC

↑ https://en.wikipedia.org/wiki/Medicines_and_Healthcare_products_Regulatory_Agency

Retrieved from "https://en.wikisage.org/w/index.php?title=Belzutifan&oldid=10625"